Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 17/20 | 0.67 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.67 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.67 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.54 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2901048 | 0.88 | MTOR (0.56) | MTORPIK3CAPIK3CDPIK3CG | |
| SCHEMBL2899990 | 0.86 | MTOR (0.52) | MTORPIK3CAPIK3CDPIK3CG | |
| SCHEMBL2906004 | 0.85 | MTOR (0.54) | MTORPIK3CAPIK3CDPIK3CG | |
| SCHEMBL2907994 | 0.84 | MTOR (0.54) | MTORPIK3CAPIK3CDPIK3CG | |
| SCHEMBL2903383 | 0.83 | MTOR (0.78) | MTORPIK3CAPIK3CD | |
| SCHEMBL2906122 | 0.83 | MTOR (0.52) | MTORPIK3CAPIK3CDPIK3CG | |
| SCHEMBL2903052 | 0.83 | PIK3CA (0.58) | MTORPIK3CAPIK3CDPIK3CG | |
| SCHEMBL2906101 | 0.83 | NPSR1 (0.54) | MTORPIK3CAPIK3CDPIK3CG | |
| SCHEMBL2906137 | 0.83 | MTOR (0.55) | MTORPIK3CAPIK3CDPIK3CG | |
| SCHEMBL2906470 | 0.82 | MTOR (0.57) | MTORPIK3CAPIK3CDPIK3CGPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217234-A2 | COMBINATIONS OF MEK INHIBITORS WITH MTOR INHIBITORS | AstraZeneca AB (SE) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009050506-A2 | COMBINATION 059 | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | WO | disclosed |
| US-20090099174-A1 | COMBINATION 059 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20080194546-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
| US-20080194546-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099174-A1 | COMBINATION 059 | MTOR, RICTOR, MAPK9 | MTOR 1/4885PIK3CA 9/4885PIK3CD 34/4885 |
| US-20080194546-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | RPS6KB1, RPS6KA1, RPS3A | MTOR 24/4885PIK3CA 729/4885PIK3CD 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.